Conduit Pharmaceuticals Announces Leadership Changes
Conduit Pharmaceuticals (Nasdaq: CDT) announced significant leadership changes as founder Dr. Andrew Regan takes over as Chief Executive Officer, replacing Dr. David Tapolczay who will transition to Head of Strategy & Licensing. Dr. Tapolczay will focus on out-licensing deals for tapinarof patents.
Dr. Regan brings extensive entrepreneurial experience, including successful ventures like Hobson Plc (sold for £154 million), founding shareholder of Asos plc (reached £4.8 billion market cap), and Imperial Energy (acquired for £1.4 billion). He holds a PhD in bio-inspired algorithm development for financial market forecasting.
The company also announced that Faith Charles will step down from the Board of Directors. Under the new leadership, Conduit aims to maximize shareholder value through licensing opportunities, creating new 20-year Composition-of-Matter patents, and utilizing AI and Cybernetics in collaboration with Sarborg for drug repurposing.
Conduit Pharmaceuticals (Nasdaq: CDT) ha annunciato importanti cambiamenti ai vertici: il fondatore Dr. Andrew Regan assume il ruolo di Amministratore Delegato, sostituendo il Dr. David Tapolczay che passerà a ricoprire la carica di Responsabile Strategia e Licensing. Il Dr. Tapolczay si concentrerà sulle operazioni di out-licensing per i brevetti di tapinarof.
Il Dr. Regan vanta una vasta esperienza imprenditoriale, con successi come Hobson Plc (venduta per 154 milioni di sterline), azionista fondatore di Asos plc (con una capitalizzazione di mercato di 4,8 miliardi di sterline) e Imperial Energy (acquisita per 1,4 miliardi di sterline). Possiede un dottorato in sviluppo di algoritmi bio-ispirati per la previsione dei mercati finanziari.
L’azienda ha inoltre comunicato che Faith Charles lascerà il Consiglio di Amministrazione. Sotto la nuova guida, Conduit punta a massimizzare il valore per gli azionisti attraverso opportunità di licensing, la creazione di nuovi brevetti di composizione della materia della durata di 20 anni e l’utilizzo di AI e cibernetica in collaborazione con Sarborg per il riposizionamento dei farmaci.
Conduit Pharmaceuticals (Nasdaq: CDT) anunció cambios importantes en su liderazgo: el fundador, Dr. Andrew Regan, asume el cargo de Director Ejecutivo, reemplazando al Dr. David Tapolczay, quien pasará a ser Jefe de Estrategia y Licencias. El Dr. Tapolczay se enfocará en acuerdos de out-licensing para las patentes de tapinarof.
El Dr. Regan aporta una amplia experiencia emprendedora, incluyendo éxitos como Hobson Plc (vendida por 154 millones de libras), accionista fundador de Asos plc (con una capitalización de mercado de 4,8 mil millones de libras) y Imperial Energy (adquirida por 1,4 mil millones de libras). Posee un doctorado en desarrollo de algoritmos bioinspirados para la predicción de mercados financieros.
La compañía también anunció que Faith Charles dejará la Junta Directiva. Bajo el nuevo liderazgo, Conduit busca maximizar el valor para los accionistas mediante oportunidades de licenciamiento, la creación de nuevas patentes de composición de materia con vigencia de 20 años y la utilización de IA y cibernética en colaboración con Sarborg para la reposición de fármacos.
Conduit Pharmaceuticals (나스닥: CDT)는 창립자 Dr. Andrew Regan이 최고경영자(CEO)로 취임하며 주요 리더십 변화를 발표했습니다. Dr. David Tapolczay는 전략 및 라이선싱 책임자로 자리를 옮겨, tapinarof 특허의 아웃라이선싱 거래에 집중할 예정입니다.
Dr. Regan은 Hobson Plc (1억 5,400만 파운드에 매각), Asos plc (시가총액 48억 파운드), Imperial Energy (14억 파운드에 인수) 등 성공적인 창업 경험을 보유하고 있으며, 금융 시장 예측을 위한 생체 영감을 받은 알고리즘 개발 박사 학위를 가지고 있습니다.
또한 회사는 Faith Charles가 이사회에서 물러난다고 발표했습니다. 새로운 리더십 하에 Conduit는 라이선싱 기회 극대화, 20년 만료의 조성물 특허 창출, Sarborg와 협력한 AI 및 사이버네틱스 활용을 통한 약물 재창출에 주력할 계획입니다.
Conduit Pharmaceuticals (Nasdaq : CDT) a annoncé d’importants changements à la direction : le fondateur, le Dr Andrew Regan, prend le poste de Directeur Général, remplaçant le Dr David Tapolczay qui deviendra Responsable de la Stratégie et des Licences. Le Dr Tapolczay se concentrera sur les accords d’out-licensing des brevets de tapinarof.
Le Dr Regan possède une vaste expérience entrepreneuriale, avec des réussites telles que Hobson Plc (vendue pour 154 millions de livres), actionnaire fondateur de Asos plc (capitalisation boursière de 4,8 milliards de livres) et Imperial Energy (acquise pour 1,4 milliard de livres). Il détient un doctorat en développement d’algorithmes bio-inspirés pour la prévision des marchés financiers.
L’entreprise a également annoncé que Faith Charles quittera le conseil d’administration. Sous cette nouvelle direction, Conduit vise à maximiser la valeur pour les actionnaires grâce à des opportunités de licences, la création de nouveaux brevets de composition de matière d’une durée de 20 ans, et l’utilisation de l’IA et de la cybernétique en collaboration avec Sarborg pour la réaffectation de médicaments.
Conduit Pharmaceuticals (Nasdaq: CDT) gab bedeutende Führungswechsel bekannt: Gründer Dr. Andrew Regan übernimmt die Position des Chief Executive Officer und ersetzt damit Dr. David Tapolczay, der zum Leiter für Strategie und Lizenzierung wechselt. Dr. Tapolczay wird sich auf Out-Licensing-Deals für Tapinarof-Patente konzentrieren.
Dr. Regan bringt umfangreiche unternehmerische Erfahrung mit, darunter erfolgreiche Unternehmen wie Hobson Plc (für 154 Millionen Pfund verkauft), Gründungsaktionär von Asos plc (Marktkapitalisierung von 4,8 Milliarden Pfund) und Imperial Energy (für 1,4 Milliarden Pfund übernommen). Er besitzt einen Doktortitel in der Entwicklung bio-inspirierter Algorithmen zur Prognose von Finanzmärkten.
Das Unternehmen gab außerdem bekannt, dass Faith Charles aus dem Vorstand ausscheidet. Unter der neuen Führung strebt Conduit an, den Aktionärswert durch Lizenzierungsmöglichkeiten, die Schaffung neuer 20-jähriger Substanzpatente und den Einsatz von KI und Kybernetik in Zusammenarbeit mit Sarborg für die Wirkstoff-Neuentwicklung zu maximieren.
- New CEO brings strong track record of building billion-dollar companies
- Former CEO remains with company to focus on licensing deals
- Strategic focus on AI and cybernetics for drug repurposing
- Company maintains continuity in leadership transition
- Multiple simultaneous leadership departures (CEO and Board member)
- Potential disruption in company direction with new leadership
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company’s next phase of growth and execution.
Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as CEO and as a member of the Board of Directors for personal reasons. Dr. Tapolczay will continue to serve the company as Head of Strategy & Licensing, ensuring continuity in strategic development and with an immediate focus on out-licensing deals for its tapinarof patents.
Dr. Regan is a successful entrepreneur with an extensive background in founding and scaling innovative companies across sectors. At the age of 29, Dr. Regan sold Hobson Plc in 1996 for
“We are grateful to David for his leadership during a pivotal time for Conduit,” said Dr. Regan. “He has laid the foundation for our future success and I am delighted that he will remain closely involved and can focus on out-licensing deals for the Company, given his excellent track-record of licensing and royalty deals in multiple pharmaceuticals products, including pembrolizumab, now marketed as Keytruda by Merck. We will maximise shareholder value at Conduit through licensing opportunities by creating new 20-year Composition-of-Matter patents, utilising cutting-edge AI and Cybernetics in collaboration with Sarborg to repurpose drugs, and by avoiding the operating inefficiencies of a traditional pharma company.”
Commenting on the transition, Dr. Tapolczay said, “It has been a privilege to serve as CEO of Conduit during this exciting phase of its evolution. I’m incredibly proud of what we have accomplished, from securing our public listing on NASDAQ to signing our license deal with AstraZeneca and advancing our pipeline towards our first clinical trial. Andrew’s entrepreneurial leadership and vision make him the right person to lead Conduit into the future, and I have full confidence in its growth under his guidance.”
The Company also announces that Faith Charles will be stepping down from the Board of Directors for personal reasons. Ms. Charles has been a key advisor and advocate for the Company during her tenure.
Chair of the Board of Directors, Dr. Freda Lewis-Hall, said, “We sincerely thank both David and Faith for their valuable contributions to Conduit’s early achievements. We welcome Andrew as CEO and are confident that under his leadership, Conduit will maximise value for patients, partners, and shareholders.”
About Conduit Pharmaceuticals
Conduit is a multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavours with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.
Investors & Media:
info@conduitpharma.com
FAQ
What leadership changes were announced at Conduit Pharmaceuticals (CDT)?
What is Dr. Andrew Regan's track record before joining Conduit Pharmaceuticals as CEO?
What will be Dr. David Tapolczay's new role at Conduit Pharmaceuticals (CDT)?
What is Conduit Pharmaceuticals' (CDT) new business strategy under Dr. Regan?
